8-K: NeuroBo Pharmaceuticals' MASH Drug Trial Clears Safety Hurdle, Phase 2a Continues

NeuroBo Pharmaceuticals announced that its Phase 2a trial for DA-1241, a potential treatment for MASH, has been recommended to continue without modification after a positive safety review.

Summary

• NeuroBo Pharmaceuticals has received approval from its Safety Review Committee (SRC) to continue its Phase 2a clinical trial of DA-1241 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
• The SRC's recommendation follows a blinded safety review of the first six months of the trial, with no significant adverse safety trends identified.
• The Phase 2a trial is designed to evaluate the efficacy and safety of DA-1241 in patients with MASH.
• The trial consists of two parts: Part 1 is evaluating DA-1241 against a placebo, and Part 2 is evaluating DA-1241 in combination with sitagliptin against a placebo.
• Part 1 is expected to enroll 49 subjects, with a maximum of 55 to account for discontinuations, and Part 2 is expected to enroll approximately 37 subjects.
• The primary endpoint for both parts of the trial is the change from baseline in alanine transaminase (ALT) levels at Week 16.
• The company anticipates a full data readout from the trial in the second half of 2024.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the successful safety review and the continuation of the trial. However, it is tempered by the fact that the trial is still ongoing and the efficacy of the drug is yet to be determined.

Positives

• The SRC approval indicates that the trial is proceeding safely, with no significant adverse safety trends observed in the first six months.
• DA-1241 has shown promise in preclinical studies, demonstrating reduced hepatic steatosis, inflammation, and fibrosis, while also improving glucose control.
• The drug was well-tolerated in Phase 1a and 1b trials in both healthy volunteers and those with type 2 diabetes mellitus.
• The trial is evaluating a potential treatment for MASH, a disease with no currently approved treatment options.

Risks

• The trial is still ongoing, and the efficacy of DA-1241 is yet to be determined.
• There is a risk that the trial may not produce positive results or that the drug may not be as effective as anticipated.
• The company's ability to execute its commercial strategy and obtain regulatory approval is subject to risks and uncertainties.
• There are risks associated with the cooperation of contract manufacturers, clinical study partners, and others involved in the development of the drug.
• Potential negative interactions between DA-1241 and other products used in combination are a risk.

Future Outlook

The company anticipates a full data readout from the Phase 2a trial in the second half of 2024.

Management Comments

• Hyung Heon Kim, President and Chief Executive Officer of NeuroBo, stated that the SRC's recommendation is an early indication of the safety of DA-1241.
• Mr. Kim also noted that DA-1241 has demonstrated reduced hepatic steatosis, hepatic inflammation and liver fibrosis, while also improving glucose control in pre-clinical and clinical evidence.

Industry Context

The development of DA-1241 is significant as there are currently no approved treatments for MASH, a growing health concern. The success of this trial could position NeuroBo as a key player in the cardiometabolic disease space.

Comparison to Industry Standards

• The Phase 2a trial design, including the use of a placebo control and a combination therapy arm, is consistent with industry standards for evaluating new treatments for MASH.
• The primary endpoint of change in ALT levels is a common measure used in MASH clinical trials, such as those conducted by Intercept Pharmaceuticals with Ocaliva and Madrigal Pharmaceuticals with Resmetirom.
• The trial's focus on safety and efficacy is in line with the regulatory requirements for drug approval, similar to the processes followed by companies like Gilead Sciences and Genfit in their MASH drug development programs.

Stakeholder Impact

• Shareholders may view the positive safety review as a positive development, potentially increasing the value of the company.
• Employees may be encouraged by the progress of the trial and the potential for a successful product launch.
• Patients with MASH may be hopeful that DA-1241 will become a viable treatment option.
• The company's suppliers and partners may benefit from the continued development of the drug.

Next Steps

• The Phase 2a trial will continue with patient enrollment and dosing.
• Another blinded SRC analysis will be conducted once the first 50% of patients have been randomized and dosed.
• The company anticipates a full data readout from the trial in the second half of 2024.

Key Dates

Keywords

MASH, DA-1241, GPR119 agonist, clinical trial, Phase 2a, safety review, metabolic dysfunction, steatohepatitis, cardiometabolic, biotechnology